Cardiovascular Event Reduction and Adverse Events Among Subjects Attaining Low-Density Lipoprotein Cholesterol <50 mg/dl With Rosuvastatin: The JUPITER Trial (Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin)

• Published in: Journal of the American College of Cardiology Vol. 57; no. 16; pp. 1666 - 1675
• Main Authors: HSIA, Judith, MACFADYEN, Jean G, MONYAK, John, RIDKER, Paul M
• Format: Journal Article
• Language: English
• Published: New York, NY Elsevier 19.04.2011; Elsevier Limited
• Subjects: Age; Aged; Biological and medical sciences; Biomarkers - blood; Blood pressure; Body mass index; Cancer; Cardiology; Cardiology. Vascular system; Cardiovascular disease; Cardiovascular Diseases - drug therapy; Cardiovascular Diseases - enzymology; Cardiovascular Diseases - mortality; Cholesterol; Cholesterol, LDL - blood; Cohort Studies; Confidence intervals; Diabetes; Female; Fluorobenzenes - adverse effects; Fluorobenzenes - therapeutic use; Follow-Up Studies; Heart attacks; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors - adverse effects; Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use; Kinases; Lipoproteins; Male; Medical sciences; Middle Aged; Mortality; Pyrimidines - adverse effects; Pyrimidines - therapeutic use; Rosuvastatin Calcium; Stroke; Sulfonamides - adverse effects; Sulfonamides - therapeutic use; Human; Prevention; Reduction; Toxicity; Use; Secondary effect; Cholesterol LDL; Complication; Statin derivative; Rosuvastatin; Circulatory system; Cardiology

The purpose of this study was to assess the impact on cardiovascular and adverse events of attaining low-density lipoprotein cholesterol (LDL-C) levels <50 mg/dl with rosuvastatin in apparently healthy adults in the JUPITER (Justification for the Use of Statins in Prevention: an Intervention Tria...